Ovarian Cancer Diagnostics Market To Reach $3.11 Billion By 2033

Ovarian Cancer Diagnostics Market Growth & Trends

The global ovarian cancer diagnostics market size is expected to reach USD 3.11 billion by 2033, registering a CAGR of 6.73% from 2025 to 2033, according to a new report by Grand View Research, Inc. The growth of the market can be attributed to an increase in the prevalence of ovarian cancer and emergence of novel diagnostic products. As of 2018, ovarian cancer had the highest mortality rate of all gynecologic cancers. It accounted for nearly 14,000 deaths in the U.S. in 2018. No specific symptoms render early diagnosis of the disease increasingly difficult. The exact causative factors remain unknown, creating a key unmet need for further research to obtain clarity on the underlying molecular mechanisms.

Women aged 60 years & above have a higher predisposition to it. As it is often diagnosed in advanced stages, treatment options are limited. Moreover, on the basis of race, incidence rates were higher among Caucasian women than African-American women. The International Federation of Gynecology and Obstetrics (FIGO) system is used for staging ovarian cancer. Staging process helps identify ovarian tumors, calculate their size, and detect invasion & metastasis.

Early detection and diagnosis significantly improve patient survival rates. For instance, in case of epithelial tumors, patients with stage 1 ovarian cancer have a survival rate of nearly 90%, whereas patients with stage 4-the most advanced phase-have a mere 15% survival rate. Technological advancements in PET and MRI as well as in diagnosis of BRCA mutations have positively impacted market growth.

The diagnostic landscape is gradually shifting toward genetic testing and counseling. As the disease bears a high risk of inheritance of gene mutation, guidelines pertaining to ovarian cancer diagnostics recommend all patients to undergo genetic counseling and testing. Earlier, BRCA1/2 was the most prominent test; however, advancements in medical science have now made it possible to test more than 20 genes in each patient.

 Request a free sample copy or view report summary: Ovarian Cancer Diagnostics Market Report

Ovarian Cancer Diagnostics Market Report Highlights

• Epithelial tumor held the largest market revenue share of 90.33% in 2024. Technological innovations in imaging techniques, molecular diagnostics, and genetic profiling are significantly enhancing the accuracy and early detection of stromal cell tumors within the global ovarian cancer diagnostics market.

• The imaging segment held the largest market revenue share of 31.95% in 2024. CT scans remain central for staging and surgical planning, but their role is increasingly complemented by PET/CT and MRI, which improve the detection of metastases and recurrence.

• The hospital laboratories segment held the highest market revenue share of 40.49% in 2024. The increasing integration of artificial intelligence (AI) and machine learning (ML) algorithms in ovarian cancer diagnostics is driving advancement in healthcare sector.

• North America held the largest share of 34.96% in 2024. Advancements in diagnostic technologies are transforming methods for diagnosis of ovarian cancer in the U.S. Techniques such as MRI and CT scans provide detailed images that help detect ovarian tumors, assess their size and spread more accurately.

• Asia Pacific is the fastest-growing region, driven by rising incidence, government-backed cancer screening initiatives, and increasing investments in diagnostic infrastructure.

Ovarian Cancer Diagnostics Market Segmentation

Grand View Research has segmented global ovarian cancer diagnostics market report based on cancer, diagnosis, end-use, and region:

Ovarian Cancer Diagnostics Cancer Outlook (Revenue, USD Million, 2021 - 2033)

• Epithelial Tumor

• Germ Cell Tumor

• Stromal Cell Tumor

• Others

Ovarian Cancer Diagnostics Diagnosis Outlook (Revenue, USD Million, 2021 - 2033)

• Imaging

  • Ultrasound

  • CT Scan

  • MRI Scan

  • PET Scan

  • Others

• Blood Test

  • CA125

  • HER2

  • BRCA

  • CEA

  • ER & PR

  • KRAS Mutation

  • Others

• Biopsy

• Others

Ovarian Cancer Diagnostics End-use Outlook (Revenue, USD Million, 2021 - 2033)

• Hospital Laboratories

• Cancer Diagnostic Centers

• Research Institutes

• Others

Ovarian Cancer Diagnostics Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • China

  • Japan

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • UAE

  • South Arabia

  • South Africa

  • Kuwait

List of Key Players in the Ovarian Cancer Diagnostics Market

• F. Hoffmann-La Roche AG

• Johnson & Johnson Services, Inc.

• GlaxoSmithKline Plc

• AstraZeneca Plc

• Siemens Healthcare GmbH

• Abbott

• Thermo Fisher Scientific

• Bio-Rad Laboratories, Inc

• Quest Diagnostics Incorporated

• Illumina, Inc